Adamson D J, Thompson W D, Dawson A A, Bennett B, Haites N E
Department of Medical Genetics, University of Aberdeen Medical School, Foresterhill, UK.
Br J Cancer. 1995 Jul;72(1):150-4. doi: 10.1038/bjc.1995.292.
Mutation and abnormal expression of p53 was studied in 38 lymphomas [five Hodgkin's disease and 33 non-Hodgkin's lymphoma (NHL)]. CM1 polyclonal antibody was used to detect overexpression of p53. Three missense mutations were characterised in three cases of NHL after screening exons 5-8 of p53 of all the tumours with single-strand conformation polymorphism (SSCP) analysis. Only two out of three tumours with a missense mutation showed abnormal expression of p53 as measured by CM1. Conversely, seven out of nine tumours with positive CM1 staining had no point mutation demonstrated. Overexpression of p53 in the cases of NHL occurred in three out of twenty four low-grade tumours and five out of nine high-grade tumours (Kiel classification). The results suggest that abnormalities of p53 are commoner in high-grade than low-grade NHL, and that positive immunocytochemistry cannot be used to determine which tumours have mutations of p53.
在38例淋巴瘤（5例霍奇金病和33例非霍奇金淋巴瘤[NHL]）中研究了p53的突变和异常表达。使用CM1多克隆抗体检测p53的过表达。通过单链构象多态性（SSCP）分析对所有肿瘤的p53外显子5-8进行筛查后，在3例NHL病例中鉴定出3个错义突变。在3个具有错义突变的肿瘤中，只有2个通过CM1检测显示p53异常表达。相反，在CM1染色阳性的9个肿瘤中，有7个未显示出点突变。在NHL病例中，p53的过表达在24个低级别肿瘤中的3个以及9个高级别肿瘤中的5个中出现（ Kiel分类）。结果表明，p53异常在高级别NHL中比低级别NHL更常见，并且免疫细胞化学阳性不能用于确定哪些肿瘤具有p53突变。
